Urica Therapeutics names Jay Kranzler as CEO

Urica Therapeutics, a Fortress Biotech (Nasdaq: FBIO) company focused on the development and commercialization of products for gout and chronic kidney disease, has announced the appointments of Jay Kranzler as chairman and chief executive, and Vibeke Strand to its board of directors.

Lindsay Rosenwald, Fortress’ chairman and chief executive and board member of Urica, said: "We are pleased to welcome Jay as chairman and chief executive officer of Urica and Vibeke to the board. Jay has been an important advisor to Fortress over the past few years. His extensive experience across all aspects of drug development will add significant value as Urica advances dotinurad for the treatment of gout and possibly other hyperuricemic indications including chronic kidney disease and heart failure."

Dr Kranzler has significant experience in a variety of roles, including as a founder, chief executive, board member and advisor to leading life science companies. He has also served in operational and consulting capacities for multiple large pharmaceutical companies, small biotech companies, investment banks and investors.